The Day In Review: Roche Promises "Stunning" Arthritis News

November 10, 2005 -- Roche promised to deliver “stunning” Phase III data on its arthritis drugs at next week’s Rheumatology meeting in San Diego; Pain Therapeutics gained 32.3% after signing a partnership with King Pharma on Remoxy, an abuse resistant opioid; Enzon Pharma received FDA approval for an IV administration of Oncaspar, a pediatric cancer drug; Aphton dissolved the Insegia pancreatic cancer partnership it had with Sanofi-Aventis; Pfizer will respond to Justice Department requests for information about physician payments for prescribing Pfizer drugs; and CombinatoRx priced its long-simmering IPO last night at $7 and closed today at $7.90. Biotech had an outstanding trading day today. The Centient Biotech 200™ rose 48 points to close at 3919.25, an increase of 1.23%. More details...

Back to news